Jonas J

2023.07.05

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

2023.06.22

I-Mab Announces the Appointment of Raj Kannan as CEO

2023.05.26

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

2023.04.26

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

2023.04.25

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

2023.04.24

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

2023.03.31

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

2023.03.20

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

2023.03.13

I-Mab Confirms No Banking Relationship with Silicon Valley Bank

2023.03.07

I-Mab Receives “A” Rating in Updated MSCI ESG Assessment